Fig. 10.
Fig. 10. Strong host resistance mediated in the absence of perforin-, FasL-, TNFR1-, and TRAIL-dependent killing. / Naive and primed B6-cdd and B6-gld (littermates) recipients received 9.0 Gy TBI 1 day prior to transplantation of 2 × 106TCD-C3H.SW bone marrow lacking TNFR1 (A) or 1 × 107TCD-BALB/c bone marrow lacking TNFR1 (B). Purified TRAIL antibody (N2B2, ▪) or an isotype-matched control antibody (░) was injected (200 μg) intraperitoneally on day 0 just prior to BM transplantation and again 24 hours later. Recipients were examined by CFU-IL3 assay. (A) Naive B6-cdd, 3682 ± 294; primed B6-cdd injected with isotype control, 80 ± 25; primed B6-cdd injected with N2B2, 7 ± 12; naive B6-gld, perf+/−, 3101 ± 353; B6-gld, perf+/−, injected with isotype control, 428 ± 16; B6-gld, perf+/−, injected with N2B2, 36 ± 12.

Strong host resistance mediated in the absence of perforin-, FasL-, TNFR1-, and TRAIL-dependent killing.

Naive and primed B6-cdd and B6-gld (littermates) recipients received 9.0 Gy TBI 1 day prior to transplantation of 2 × 106TCD-C3H.SW bone marrow lacking TNFR1 (A) or 1 × 107TCD-BALB/c bone marrow lacking TNFR1 (B). Purified TRAIL antibody (N2B2, ▪) or an isotype-matched control antibody (░) was injected (200 μg) intraperitoneally on day 0 just prior to BM transplantation and again 24 hours later. Recipients were examined by CFU-IL3 assay. (A) Naive B6-cdd, 3682 ± 294; primed B6-cdd injected with isotype control, 80 ± 25; primed B6-cdd injected with N2B2, 7 ± 12; naive B6-gld, perf+/−, 3101 ± 353; B6-gld, perf+/−, injected with isotype control, 428 ± 16; B6-gld, perf+/−, injected with N2B2, 36 ± 12.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal